Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: busulfan
Drug: tacrolimus
Drug: methotrexate
Genetic: cytogenetic analysis
Other: flow cytometry
Other: pharmacological study
Other: pharmacogenomic studies
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2007-03-09

Last Posted Date: 2018-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00445744

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Secondary Myelofibrosis

First Posted Date: 2007-03-09

Last Posted Date: 2011-03-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 22

Registration Number: NCT00445900

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

First Posted Date: 2007-03-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00003552

Locations: 🇺🇸
National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Phase 1

Terminated

Conditions: Recurrent Pediatric ALL
Acute Lymphoblastic Leukemia
Refractory Pediatric ALL
Relapsed Pediatric ALL

Interventions: Drug: ABT-751
Drug: Dexamethasone
Drug: PEG-asparaginase
Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Cyclophosphamide
Drug: 6-thioguanine

First Posted Date: 2007-02-23

Last Posted Date: 2021-03-17

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 9

Registration Number: NCT00439296

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 2 locations

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-02-22

Last Posted Date: 2009-03-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT00438841

Locations: 🇺🇸
Oregon Health and Science University Cancer Institute, Portland, Oregon, United States
🇺🇸
Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 7 locations

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: cyclophosphamide
Biological: therapeutic autologous lymphocytes
Biological: aldesleukin
Other: immunohistochemistry staining method
Procedure: biopsy
Other: laboratory biomarker analysis
Other: immunologic technique
Genetic: polymerase chain reaction

First Posted Date: 2007-02-22

Last Posted Date: 2012-03-16

Lead Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Target Recruit Count: 11

Registration Number: NCT00438984

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2

Completed

Conditions: Cardiac Toxicity
Breast Cancer

First Posted Date: 2007-02-19

Last Posted Date: 2022-08-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 122

Registration Number: NCT00436566

Locations: 🇺🇸
Mayo Clinic Cancer Research Consortium, Rochester, Minnesota, United States

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Not Applicable

Conditions: Breast Cancer

First Posted Date: 2007-02-19

Last Posted Date: 2014-01-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT00436709

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2007-02-12

Last Posted Date: 2024-05-08

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 2000

Registration Number: NCT00433420

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2007-02-12

Last Posted Date: 2012-07-30

Lead Sponsor: National Cancer Institute, Naples

Registration Number: NCT00434031

Locations: 🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy